New Antibody Promising for Relapsed Lymphoma – Clinical Oncology News
 Clinical Oncology News | New Antibody Promising for Relapsed Lymphoma Clinical Oncology News San Diego—In the first head-to-head comparison, obinutuzumab (GA101, Genentech) appeared to be more active than rituximab in relapsed CD20-positive indolent B-cell non-Hodgkin's lymphoma (NHL). Although only a Phase II study, the multinational, ... |
Immune drug doesn’t help kids with hard-to-treat kidney disorder – EurekAlert (press release)
Immune drug doesn't help kids with hard-to-treat kidney disorder EurekAlert (press release) Children with a particular kidney immune disorder that is unresponsive to standard treatments do not benefit from the immune drug rituximab. Additional studies are needed to fully understand the disease and to develop effective therapies for ... |
Cell Therapeutics’ Pixuvri® Approved in European Union as Monotherapy to Treat … – MarketWatch (press release)
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat ... MarketWatch (press release) The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after 1 to 3 ... |
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent … – Sacramento Bee
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent ... Sacramento Bee The poster discussion session will highlight data from the ibrutinib Phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients. Oral Presentation Date/Time: Monday, June 4, 2012; 10:15 AM – 10:30 AM (CT) ... |
CHOP-RIT, CHOP-R Similar for Follicular Lymphomas – Clinical Oncology News
 Clinical Oncology News | CHOP-RIT, CHOP-R Similar for Follicular Lymphomas Clinical Oncology News San Diego—Radiolabeled iodine-131 tositumomab (RIT) and rituximab have similar efficacy and tolerability when either is combined with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) for newly diagnosed follicular non-Hodgkin's ... |
Daiichi Sankyo teams up with US firm to develop biosimilars – Mainichi Daily News
Daiichi Sankyo teams up with US firm to develop biosimilars Mainichi Daily News Daiichi Sankyo will introduce relevant technology from Coherus BioSciences to develop biosimilar forms of etanercept for rheumatism treatment and rituximab for cancer treatment. The Japanese drugmaker will put them on sale in Japan, South Korea and ... Daiichi Sankyo, Coherus partner to develop biosimilar candidates Coherus launches with Daiichi Sankyo biosimilar pact |
Meeting the Challenges in Treating Lymphoma A Conversation With Andrew D … – OncLive
 OncLive | Meeting the Challenges in Treating Lymphoma A Conversation With Andrew D ... OncLive Dr Zelenetz: The standard of care for diffuse large B-cell lymphoma (DLBCL) in the United States remains rituximab (R) in combination with cyclophosphamide, doxorubicin, vincristine, and predisone (CHOP) given every 21 days. |
Compulsory licensing sets off a wave of price cuts in cancer drugs – Livemint
Compulsory licensing sets off a wave of price cuts in cancer drugs Livemint Some of the key cancer drugs under patent protection in India—erlotinib (lung cancer), sunitinib (kidney cancer), sorafenib (liver and kidney cancer), trastuzumab (breast cancer) and rituximab (blood and lymphatic cancer)—are neither subjected to ... |
Rituximab Promotes Long-Term Response for Patients with Immune Destruction of … – Business Review India (press release)
Rituximab Promotes Long-Term Response for Patients with Immune Destruction of ... Business Review India (press release) WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet ... |
Rituximab promotes long-term response for patients with immune destruction of … – Medical Xpress
Rituximab promotes long-term response for patients with immune destruction of ... Medical Xpress A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic ... |